New Delhi -°C
Today in New Delhi, India

Nov 24, 2020-Tuesday
-°C

Humidity
-

Wind
-

Select Country
Select city
ADVERTISEMENT
Home / India News / Serum Institute to resume Covid-19 vaccine trial after DGCI gives nod

Serum Institute to resume Covid-19 vaccine trial after DGCI gives nod

Good news, tweets Serum Institute of India CEO Adar Poonawalla, after Astrazeneca announced it has got a go-ahead from British regulators.

india Updated: Sep 13, 2020, 00:12 IST
hindustantimes.com | Edited by Poulomi Ghosh
hindustantimes.com | Edited by Poulomi Ghosh
Hindustan Times, New Delhi
Covid-19 vaccine trials in India will begin only after India’s drug controller gives a nod,  says Serum Institute of India.
Covid-19 vaccine trials in India will begin only after India’s drug controller gives a nod, says Serum Institute of India.(Reuters)

After pharma company AstraZeneca announced the resumption of its Covid-19 vaccine trial in the UK, its India partner Serum Institute said it will also restart the trials once the Drug Controller General of India (DGCI) gives the nod.

DGCI has earlier sent a show-cause notice to the Pune-based firm, questioning why it has not stopped trials while trials have been stopped in four other countries after a UK volunteer reportedly showed symptoms of neurological disorder which affects the spinal cord. Following this, Serum Institute of India paused the phase 3 trial in India, which was scheduled to begin next week.

Also Read | Oxford’s coronavirus vaccine AstraZeneca trial resumes after UK green light

“Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so,” AstraZeneca said in a statement on Saturday.

 

“As I’d mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events are a clear example why we should not bias the process and should respect the process till the end. Good news, @UniofOxford,” Serum Institute of India’s CEO Adar Poonawalla tweeted after AstraZeneca announced it is resuming the trials.

The World Health Organization’s (WHO) chief scientist on Thursday said AstraZeneca’s pause of an experimental vaccine for the coronavirus after the illness of a participant is a “wake-up call”. “This is a wake-up call to recognise that there are ups and downs in clinical development and that we have to be prepared,” Soumya Swaminathan said.

ht epaper

Sign In to continue reading